These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 23708073

  • 1. Predictors of biomarkers guiding targeted therapeutic strategies in locally advanced lung cancer.
    Cottini F, Lautenschlaeger T.
    Cancer J; 2013; 19(3):263-71. PubMed ID: 23708073
    [Abstract] [Full Text] [Related]

  • 2. [Molecular pathology of lung cancer: key to personalized medicine].
    Cheng L, Li Y, Zhang SB, Teng XD.
    Zhonghua Bing Li Xue Za Zhi; 2012 Oct; 41(10):715-20. PubMed ID: 23302321
    [No Abstract] [Full Text] [Related]

  • 3. Targeted treatment for lung cancer could be possible due to identification of nonuniform genetic mutations.
    Jones S.
    Pharmacogenomics; 2014 May; 15(7):903-4. PubMed ID: 25090664
    [No Abstract] [Full Text] [Related]

  • 4. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.
    Brugger W, Triller N, Blasinska-Morawiec M, Curescu S, Sakalauskas R, Manikhas GM, Mazieres J, Whittom R, Ward C, Mayne K, Trunzer K, Cappuzzo F.
    J Clin Oncol; 2011 Nov 01; 29(31):4113-20. PubMed ID: 21969500
    [Abstract] [Full Text] [Related]

  • 5. Lung Cancer Genomics in the Era of Accelerated Targeted Drug Development.
    Wijesinghe P, Bollig-Fischer A.
    Adv Exp Med Biol; 2016 Nov 01; 890():1-23. PubMed ID: 26703796
    [Abstract] [Full Text] [Related]

  • 6. ALK, lung cancer, and personalized therapy: portent of the future?
    Garber K.
    J Natl Cancer Inst; 2010 May 19; 102(10):672-5. PubMed ID: 20460631
    [No Abstract] [Full Text] [Related]

  • 7. INTERESTing biomarker to select IDEAL patients for epidermal growth factor receptor tyrosine kinase inhibitors: yes, for EGFR mutation analysis, others, I PASS.
    Govindan R.
    J Clin Oncol; 2010 Feb 10; 28(5):713-5. PubMed ID: 20038722
    [No Abstract] [Full Text] [Related]

  • 8. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.
    Douillard JY, Shepherd FA, Hirsh V, Mok T, Socinski MA, Gervais R, Liao ML, Bischoff H, Reck M, Sellers MV, Watkins CL, Speake G, Armour AA, Kim ES.
    J Clin Oncol; 2010 Feb 10; 28(5):744-52. PubMed ID: 20038723
    [Abstract] [Full Text] [Related]

  • 9. Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study.
    Schneider CP, Heigener D, Schott-von-Römer K, Gütz S, Laack E, Digel W, Guschall WR, Franke A, Bodenstein H, Schmidtgen C, Reck M.
    J Thorac Oncol; 2008 Dec 10; 3(12):1446-53. PubMed ID: 19057271
    [Abstract] [Full Text] [Related]

  • 10. The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
    Fiala O, Pesek M, Finek J, Benesova L, Belsanova B, Minarik M.
    Cancer Genet; 2013 Dec 10; 206(1-2):26-31. PubMed ID: 23313110
    [Abstract] [Full Text] [Related]

  • 11. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.
    Khambata-Ford S, Harbison CT, Hart LL, Awad M, Xu LA, Horak CE, Dakhil S, Hermann RC, Lynch TJ, Weber MR.
    J Clin Oncol; 2010 Feb 20; 28(6):918-27. PubMed ID: 20100958
    [Abstract] [Full Text] [Related]

  • 12. Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status.
    Metro G, Chiari R, Bennati C, Cenci M, Ricciuti B, Puma F, Flacco A, Rebonato A, Giannarelli D, Ludovini V, Bellezza G, Ferolla P, Minotti V, Crinò L.
    Clin Lung Cancer; 2014 Jan 20; 15(1):86-92. PubMed ID: 24139827
    [Abstract] [Full Text] [Related]

  • 13. Non-small cell lung cancer--genetic predictors.
    Koudelakova V, Kneblova M, Trojanec R, Drabek J, Hajduch M.
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2013 Jun 20; 157(2):125-36. PubMed ID: 23733083
    [Abstract] [Full Text] [Related]

  • 14. Management of Italian patients with advanced non-small-cell lung cancer after second-line treatment: results of the longitudinal phase of the LIFE observational study.
    de Marinis F, Ardizzoni A, Fontanini G, Grossi F, Cappuzzo F, Novello S, Santo A, Lorusso V, Cortinovis D, Iurlaro M, Galetta D, Gridelli C, LIFE Study Team.
    Clin Lung Cancer; 2014 Sep 20; 15(5):338-45.e1. PubMed ID: 24925809
    [Abstract] [Full Text] [Related]

  • 15. Current drugs and drug targets in non-small cell lung cancer: limitations and opportunities.
    Daga A, Ansari A, Patel S, Mirza S, Rawal R, Umrania V.
    Asian Pac J Cancer Prev; 2015 Sep 20; 16(10):4147-56. PubMed ID: 26028064
    [Abstract] [Full Text] [Related]

  • 16. KRAS mutations as prognostic and predictive markers in non-small cell lung cancer.
    Martin P, Leighl NB, Tsao MS, Shepherd FA.
    J Thorac Oncol; 2013 May 20; 8(5):530-42. PubMed ID: 23524403
    [Abstract] [Full Text] [Related]

  • 17. A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903).
    Matsumoto Y, Maemondo M, Ishii Y, Okudera K, Demura Y, Takamura K, Kobayashi K, Morikawa N, Gemma A, Ishimoto O, Usui K, Harada M, Miura S, Fujita Y, Sato I, Saijo Y, North-East Japan Study Group.
    Lung Cancer; 2014 Nov 20; 86(2):195-200. PubMed ID: 25249428
    [Abstract] [Full Text] [Related]

  • 18. KRAS mutation: should we test for it, and does it matter?
    Roberts PJ, Stinchcombe TE.
    J Clin Oncol; 2013 Mar 10; 31(8):1112-21. PubMed ID: 23401440
    [Abstract] [Full Text] [Related]

  • 19. Targeting the MET gene for the treatment of non-small-cell lung cancer.
    Gelsomino F, Facchinetti F, Haspinger ER, Garassino MC, Trusolino L, De Braud F, Tiseo M.
    Crit Rev Oncol Hematol; 2014 Feb 10; 89(2):284-99. PubMed ID: 24355409
    [Abstract] [Full Text] [Related]

  • 20. Molecular alterations in non-small cell lung carcinomas of the young.
    VandenBussche CJ, Illei PB, Lin MT, Ettinger DS, Maleki Z.
    Hum Pathol; 2014 Dec 10; 45(12):2379-87. PubMed ID: 25288236
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.